SavedAdd your journal

Journals / Sakarya Tıp Dergisi / 2026 / Volume: 10 Issue: 2

The Effect of Anthracycline Chemotherapy on Arterial Stiffness

Antrasiklin Kemoterapisinin Arteriyel Sertlik Üzerine Etkisi

Oguzhan Ekrem Turan(FACULTY OF MEDICINE)0000-0003-3557-1682
Mustafa Yılmaz(FACULTY OF MEDICINE)0000-0002-1816-0729
Mürsel Şahin(FACULTY OF MEDICINE)0000-0003-0245-2038
Pages
—
Publication Date
2020-06-15
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We aimed to investigate the relationship between chemotherapy and arterial stiffness.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Anthracycline-derived chemotherapy for cancer treatment may cause dose-dependent irreversible heart failure.
📊
Key Findings & Data:Arterial stifness is a predictor of cardiovascular events.
💡
Conclusion & Impact:We aimed to investigate the relationship between chemotherapy and arterial stiffness.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Chemotherapy · arterial stiffness · anthracyclin

Abstract

Objective: Anthracycline-derived chemotherapy for cancer treatment may cause dose-dependent irreversible heart failure. Arterial stifness is a predictor of cardiovascular events. We aimed to investigate the relationship between chemotherapy and arterial stiffness.

Özet

Öz:

🔖

Cite This Article

Turan, O. E., Yılmaz, M., Şahin, M. (2020). The Effect of Anthracycline Chemotherapy on Arterial Stiffness. Sakarya Tıp Dergisi, Volume: 10 Issue: 2. https://doi.org/10.31832/smj.673754

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (21)

  1. Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011;7:214–220.
  2. Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB.Anthracycline cardiotoxicity: From bench to bedside. J Clin Oncol 2008;26:3777-3784.
  3. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med.1998;339:900-905.
  4. Carver JR, Shapiro CL, Ng A,Jacobs L, Schwartz C, Virgo KS, Hagerty KL et al.: American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. J Clin Oncol 2007;25:3991-4008.
  5. Shirwany NA, Zou MH. Arterial stiffness: a brief review. Acta Pharmacol Sin 2010;31:1267–1276.
  6. Franklin SS, Gustin Wt, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997;96:308–15.
  7. Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkitachalam L, Kupelian V, Simonsick EM, et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005;111:3384–90.
  8. Chae CU, Pfeffer MA, Glynn RJ, Mitchell GF, Taylor JO, Hennekens CH. Increased pulse pressure and risk of heart failure in the elderly. JAMA 1999;281:634–9. Herceg-Cavrak V, ⦁ Ahel V, ⦁ Batinica M, ⦁ Matec L, Kardos D. Increased arterial stiffness in children treated with anthracyclines for malignant disease. ⦁ Coll Antropol. 2011;35:389-95.
  9. Herceg-Cavrak V, ⦁ Ahel V, ⦁ Batinica M, ⦁ Matec L, Kardos D. Increased arterial stiffness in children treated with anthracyclines for malignant disease. ⦁ Coll Antropol. 2011;35:389-95.
  10. Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 2010;28:166-72.
  11. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D et al. European Network for Non-invasive Investigation of Large Arteries.Expert consensus document on arterial stiffness: methodological issues and clinical applications.Eur Heart J 2006;27:2588-605.
  12. Pauca AL, O'Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001;38:932-7
  13. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 2000;15:263-70.
  14. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig Met al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.
  15. Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. Circ Heart Fail 2016;9:e002661.
  16. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc Drugs Ther 2017;31:63–75.
  17. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900–5.
  18. Wolf MB, Baynes JW. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta 2006;1760: 267-71.
  19. Duquaine D, Hirsch GA, Chakrabarti A, Han Z, Kehrer C, Brook R et al. Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase. Vasc Med 2003;8:101-7.
  20. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda Set al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99:1141–1146.
  21. Gedikli O, Ozturk S, Yilmaz H, Baykan M, Kiris A, Durmus Iet al: Low total antioxidative capacity levels are associated with augmentation index but not pulse-wave velocity. Heart Vessels 2009;24:366-70